Oral Sabizabulin reduces mortality in hospitalized COVID-19 patients at high risk for ARDS
Michael Gordon, MD, CMO at HonorHealth Research and Innovation Institute, delivers a presentation on one of our COVID-19 trials and the NEJM publication for the same trial. The presentation is about 10 minutes in length and can be viewed here.